Ascension’s $3.9B AmSurg Deal Signals New ASC Antitrust Era

Bypaulgruensfelder
Becker’s ASC Review June 4, 2026
Read Full Article →
AI-Generated Summary

Ascension completed its $3.9 billion acquisition of AmSurg on June 4, 2026, expanding its ambulatory surgery center network from 58 to more than 300 facilities across 34 states — making it one of the largest ASC operators in the U.S. alongside Tenet’s USPI and SCA Health. The FTC required Ascension to divest seven ASCs in Tennessee, Florida, Oklahoma, Texas, and Kansas to preserve local competition, with six going to SCA Health (an Optum subsidiary) and one transferring to a physician group. For 10 years, Ascension must give the FTC advance notice before acquiring any ASCs near the divested markets. The consent order marks the first time the FTC has scrutinized an ASC deal at this scale, signaling new antitrust attention on outpatient surgery consolidation.

Why It Matters

This deal signals that ASC consolidation now draws the same local-market antitrust scrutiny long applied to hospitals and payers — PE-backed and health-system ASC platforms pursuing roll-ups should expect longer FTC timelines, mandated divestitures, and post-close monitoring in concentrated metros.

ASC consolidation antitrust scrutiny FTC divestiture ambulatory surgery M&A health system growth strategy market concentration healthcare PE rollup

While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.

Frequently asked questions

Why did the FTC require Ascension to divest 7 ASCs in its $3.9B AmSurg deal?

The FTC’s June 2026 consent order found the deal would otherwise threaten competition in five states — Tennessee, Florida, Oklahoma, Texas, and Kansas. Six of the divested centers went to SCA Health (an Optum subsidiary) and one transferred to a physician group with an existing minority stake.

How many ASCs does Ascension now operate after the AmSurg acquisition?

Ascension’s ASC footprint grew from 58 centers to more than 300 across 34 states, placing it among the largest ASC operators nationally alongside Tenet’s United Surgical Partners International and SCA Health.

What ongoing FTC obligations does Ascension face after closing the AmSurg deal?

For 10 years, Ascension must provide the FTC advance notice before acquiring any ASCs in metro areas surrounding the divested facilities. A monitor will also oversee compliance with transition and divestiture obligations for up to one year.

Similar Posts

  • How RCM Performance Drives ASC Valuation Multiples in 2026

    Bypaulgruensfelder

    Ambulatory surgery centers preparing to sell in 2026 are seeing buyers price deals on revenue cycle performance as much as case volume, according to VMG Health. Historical ASC sale multiples have run 7-8x EBITDA, with best-in-class centers commanding double-digit multiples, but VMG Health’s deal team says buyers now apply heavier diligence to collections discipline, payer mix, and denial management before underwriting that premium. The firm, drawing on transactions led by Christa Shephard, Chad Zoretic, Debra Stinchcomb, and Nancy Stephens, also flags leadership and management infrastructure and physician alignment as valuation drivers distinct from financial metrics, since centers dependent on one or two physicians or lacking a transferable management layer carry higher post-close execution risk that buyers price into their offers.

  • Optimizely Enters the AEO Race With Agent Visibility Analytics

    Bypaulgruensfelder

    Optimizely launched a full Answer Engine Optimization (AEO) platform on June 10, 2026, introducing Agent Visibility Analytics and a new data-sharing partnership with Conductor. Built inside Optimizely Analytics, the tool uses log-level data, not modeled estimates, to show which AI agents and crawlers are accessing a site’s content, classified by intent and broken out by funnel stage or topic area. The launch pairs that visibility layer with two autonomous agents: one that flags content gaps versus competitors in AI search results, and one that benchmarks AI-driven share of voice. The release follows similar AEO moves from Siteimprove, HubSpot, Webflow, and Sitecore, as Google’s AI Mode surpasses 1 billion monthly active users.

  • CMS Proposes 2027 Physician Payment Overhaul: MIPS Sunset and ACO Expansion

    Bypaulgruensfelder

    CMS’s proposed CY 2027 Physician Fee Schedule rule would sunset traditional MIPS reporting in 2029, replace it with specialty-focused MIPS Value Pathways covering roughly 98% of specialties, and make Medicare ACOs easier to join and more rewarding. The Medicare Shared Savings Program — which paid $4.1 billion in shared savings to 75% of its 476 ACOs for 2024 while generating about $2.5 billion in net Medicare savings — would gain new-entrant financial incentives, more predictable spending benchmarks, and the option to reduce beneficiary cost-sharing starting April 2027. CMS also proposes recalibrating physician payment rates, introducing MIPS Core Measures in 2027, and closing an APM incentive loophole worth an estimated $2.38 billion over a decade.

  • The Attribution Problem Your Board Doesn’t Understand

    Bypaulgruensfelder

    Healthcare marketing attribution is genuinely hard for multi-site groups because patient journeys are long, largely offline, and privacy-constrained—and a budget you can’t defend is a budget that gets cut. Strategy Collective’s Matt Lee argues perfect attribution doesn’t exist, but ‘good enough’ attribution is achievable through four moves: call tracking, redesigned patient intake questions, a blended market-level report, and separating brand demand from generated demand. The bigger fix is reframing the board conversation itself. Instead of asking ‘is marketing working?’, leaders should ask ‘how do we make Market B look like Market A?’—shifting from an unwinnable ROI-proof debate to a comparative, market-level view that drives real reallocation decisions.

  • Q3 2026 AI Trends: What Growth Leaders Need to Track

    Bypaulgruensfelder

    The most useful AI question for growth-stage leaders in Q3 2026 has shifted from what models can do to what results they actually deliver. Summit Partners’ AI and data science team flags five developments to track: the conversation has moved from capability to production results; the binding constraint is rarely the model itself but data, workflow, and integration; agents are evolving from assistants to actors, with trust as the real limiting factor; the underlying economics of AI are being rewritten; and leaders must separate genuine signal from noise while recognizing what work stays human. The throughline is disciplined execution—turning promising pilots into dependable, measurable production systems.

  • PE’s Quieter Playbook: Joint Ventures With Nonprofit Health Systems

    Bypaulgruensfelder

    Private equity firms are increasingly expanding in healthcare through joint ventures with nonprofit health systems rather than outright buyouts, according to a new report from the Private Equity Stakeholder Project. The report finds 21.4% of private equity-owned hospitals are held through joint venture arrangements with nonprofit systems, and the structure now spans hospitals, inpatient rehab, hospice, home health, behavioral health, ambulatory surgery centers and urgent care — likely an undercount, since the tally covers only publicly identifiable arrangements. Case studies include ventures involving Lifepoint Health, Compassus, Ardent Health Services and Ascension. PESP argues these JVs have drawn far less scrutiny than traditional PE buyouts even as they become more common, prompting calls for greater oversight.